OnKure Therapeutics, Inc. Total Assets
OnKure Therapeutics, Inc. total assets. Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) holds total assets worth $179.35 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see OnKure Therapeutics, Inc. stock valuation for the company's overall valuation and market capitalisation.
Total Assets of OnKure Therapeutics, Inc. (2020–2025)
Total assets of OnKure Therapeutics, Inc. from 2020 to 2025. This chart illustrates how OnKure Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data. See OnKure Therapeutics, Inc. stock price for real-time trading data and today's change.
OnKure Therapeutics, Inc. - Asset Composition Analysis
OnKure Therapeutics, Inc. Total Assets Breakdown (December 2025)
OnKure Therapeutics, Inc. total assets breakdown as of December 2025. OnKure Therapeutics, Inc.'s total assets of $179.35 Million consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how OnKure Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore OKUR net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: OnKure Therapeutics, Inc.'s current assets represent 97.9% of total assets in 2025, a decrease from 99.7% in 2020.
- Cash Position: Cash and equivalents constituted 95.1% of total assets in 2025, down from 97.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
OnKure Therapeutics, Inc. Competitors by Total Assets
Key competitors of OnKure Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
OnKure Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 26.75 | 11.13 | 10.65 |
| Quick Ratio | 26.75 | 11.13 | 10.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $171.03 Million | $76.95 Million | $132.58 Million |
OnKure Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between OnKure Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.97 |
| Latest Market Cap to Assets Ratio | 1.69 |
| Asset Growth Rate (YoY) | -45.9% |
| Total Assets | $62.12 Million |
| Market Capitalization | $104.89 Million USD |
Valuation Analysis
Above Book Valuation: The market values OnKure Therapeutics, Inc.'s assets above their book value (1.69x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: OnKure Therapeutics, Inc.'s assets decreased by 45.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for OnKure Therapeutics, Inc. (2020–2025)
The table below shows the annual total assets of OnKure Therapeutics, Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $62.12 Million | -45.94% |
| 2024-12-31 | $114.91 Million | +221.56% |
| 2023-12-31 | $35.73 Million | +123.35% |
| 2022-12-31 | $16.00 Million | -89.61% |
| 2021-12-31 | $154.02 Million | +178.92% |
| 2020-12-31 | $55.22 Million | -- |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more